Clinical trials: Pegfilgrastim
Breast Cancer, Neutropenia
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
RATIONALE: Colony-stimulating factors, such as filgrastim or pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of…
- Trial name
- NCT00030758
- Testing
- filgrastim, pegfilgrastim
- Where
- 32 sites in United Kingdom
- Volunteers
- 816 people
- Sponsor
- Anglo Celtic Cooperative Oncology Group
Neuroblastoma
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy…
- Trial name
- NCT03107988
- Testing
- Lorlatinib, Cyclophosphamide, Topotecan
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Solid Malignancies
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
Hypothesis: pegfilgrastim at 300 µg/kg in hematological steady state provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study.
- Trial name
- NCT00695370
- Testing
- Pegfilgrastim (drug)
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Lymphoma, Non Hodgkin's Lymphoma
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
We now propose to investigate the combination of CHOP-Rituxan plus PEG-Filgrastim (PEG-filgrastim) and GM-CSF. PEG-Filgrastim would be given in order to allow us to administer the chemotherapy courses every 2 weeks with the…
- Trial name
- CHOP-R (NCT01527422)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
- Where
- Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Fernando Cabanillas
Chemotherapy-induced Neutropenia
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
The present study was an observational, multicenter, non-interventional, single arm, open label, PMS study conducted in Iran. The primary objective of this study was safety assessment, including the rate of AEs.
- Trial name
- NCT04460079
- Testing
- Peg-filgrastim
- Volunteers
- 654 people
- Sponsor
- Cinnagen
Hodgkin's Disease, Lymphoma
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
The standard treatment for patients with HL that has not responded to treatment or has come back after treatment is stem cell transplant.
- Trial name
- NCT00705250
- Testing
- bendamustine hcl
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Peripheral T-Cell Lymphoma
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
- Trial name
- NCT00632827
- Testing
- Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00470366
- Testing
- pegfilgrastim, cisplatin, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Medulloblastoma
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
- Trial name
- NCT05535166
- Testing
- Surgical resection, Ommaya/VPS, Methotrexate
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- St. Jude Children's Research Hospital
Breast Cancer
Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer
This is a prospective, non-interventional, single arm study, which is examining doxorubicin and cyclophosphamide (AC) once every 2 weeks with lipegfilgrastim support in early breast cancer.
- Trial name
- NCT02527317
- Testing
- Lipegfilgrastim
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Beaumont Hospital
Diffuse Large B Cell Lymphoma, Neutropenia, Febrile
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim.
- Trial name
- NCT02474550
- Where
- 24 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- Ajou University School of Medicine
Breast, Breast Cancer
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
The overall purpose of this study is to investigate whether younger subjects report pain with pegfilgrastim (or biosimilar substitution) more often and/or at higher levels (greater intensity) than older subjects.This study will…
- Trial name
- NCT04174742
- Testing
- pegfilgrastim
- Where
- 2 sites in United States
- Volunteers
- 115 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
In this trial investigators propose to assess the dose dense, G-CSF supported sequential administration of 4 cycles of FEC followed by 4 cycles of docetaxel versus 6 cycles of docetaxel/cyclophosphamide as adjuvant chemotherapy…
- Trial name
- NCT01985724
- Testing
- Docetaxel, Epirubicin, Cyclophosphamide
- Where
- 10 sites in Greece
- Volunteers
- 650 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080626
- Testing
- pegfilgrastim, docetaxel, conventional surgery
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Urothelial Carcinoma
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
There is no accepted standard chemotherapy approved for use in the second line for patients with advanced urothelial carcinoma whose cancer has progressed on combination chemotherapy including either cisplatin or carboplatin.
- Trial name
- NCT01437488
- Testing
- Cabazitaxel, Neulasta, CT Scan
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Bladder Cancer
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy.
- Trial name
- TroFuse-031 (NCT07419295)
- Testing
- Sacituzumab tirumotecan, Vinflunine, Docetaxel
- Where
- 111 sites in United States, Argentina and 15 more
- Volunteers
- 590 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Treatment for Elderly Patients With High Risk Breast Cancer
This open-label, multicenter study explored primary and secondary prophylaxis treatment with a single, fixed-dose, subcutaneous (SC) injection of pegfilgrastim in elderly subjects with high-risk breast cancer receiving…
- Trial name
- NCT00117910
- Testing
- pegfilgrastim
- Sponsor
- Amgen
Metastatic Triple Negative Breast Cancer
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or…
- Trial name
- NCT02834403
- Testing
- L-NMMA, Docetaxel, Amlodipine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The Methodist Hospital Research Institute
Triple-Negative Breast Cancer
An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy
This open-label, prospective, single-arm clinical study aims to evaluate the efficacy and safety of pegfilgrastim in preventing febrile neutropenia (FN) among patients with triple-negative breast cancer (TNBC) receiving…
- Trial name
- NCT07525869
- Testing
- Pegfilgrastim (Neulasta)
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Neutropenia
A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants
This study is for healthy participants. This study tests single dose of the research drug HSP-130 against two existing approved drugs United States - approved Neulasta and European Union-approved Neulasta.
- Trial name
- NCT02629289
- Testing
- HSP-130, US-approved Neulasta, EU-approved Neulasta
- Where
- Australia
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Pfizer